CytoSorbents Corp (CTSO): Enterprise Value to EBITDA Ratio
The EV/EBITDA market price visualization for Cytosorbents (CTSO) is 0.00. Cytosorbents leads the blood filtration segment by creating unique columns to combat sepsis and toxins. Global demand for extracorporeal therapy is steadily growing due to the expansion of intensive care unit networks. The business relies on regular sales of high-margin replacement cartridges, which ensure a constant cash flow from the installed equipment base.
Comprehensive metric breakdowns and analytics for cytosorbents.com (CTSO)
- stock price and consensus target price:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Cytosorbents|CTSO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity CytoSorbents Corporation|CTSO - Company Total Debt|Debts to Book Capitalization CytoSorbents Corporation|CTSO - Long-Term Debt|Company Short-Term Debts Cytosorbents|Quick Ratio cytosorbents.com
- financial results and valuation multiples details:
CTSO - Net Financial Result|Projected Future Earnings Cytosorbents|CTSO - Price to Earnings Ratio|Forward P/E Multiple CytoSorbents Corporation|CTSO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoSorbents Corporation|CTSO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Cytosorbents|CTSO - Earnings per share for the trailing year|Quarterly EPS earnings growth cytosorbents.com|CTSO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cytosorbents
Analysis of all company metrics:CytoSorbents Corp. CTSO
Steady demand for blood purification systems in intensive care units creates a reliable cash flow for Cytosorbents (CTSO), which is assessed via the EV/EBITDA multiple chart. This metric compares the total enterprise value, including debt, against operating profit, allowing investors to determine if the asset is overvalued or to identify an entry point when fundamental indicators are undervalued.
Competitor analysis
Dexcom Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Penumbra Medical PEN|NOVT: Enterprise Value to EBITDA Ratio|haemonetics.com - Enterprise Value to Operating Income Before Depreciation Ratio|INSP: EV/EBITDA Multiple|PRCT - Total Company Value to Operating Income Before Depreciation Ratio|CNMD (CONMED Corp.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulse Medical (PLSE)|Enterprise Value to EBITDA Ratio INMD (InMode Ltd.)|PMI (picardmedical.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Surmodics SRDX|SENS - Enterprise Value to EBITDA Ratio|NeuroPace Corp - EV/EBITDA Multiple|Company Value to EBITDA Tactile Systems Technology|SNWV: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation OM|ELMD (SmartVest) - EV/EBITDA Multiple|LENSAR Inc. (LNSR) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCEL|Enterprise Value to EBITDA Ratio profoundmedical.com PROF|EV/EBITDA Multiple BDMD (Baird Medical)|EV/EBITDA Multiple EDAP TMS SA EDAP|APYX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ICCM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LUNG (pulmonx.com) - Enterprise Value to EBITDA Ratio|TELA Bio - Business Value to Operating Income Before Depreciation|SRTS (Sensus Healthcare, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA zynex.com ZYXI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization electroCore, Inc. (ECOR)|vicarioussurgical.com (RBOT) - Enterprise Value to EBITDA Multiple|Inspira Technologies - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple SeaStar Medical Holding Corp. ICU|IRIDEX Corp. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Intelligent Bio Solutions INBS|beyondair.net (XAIR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PFSA (Profusa Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization STRATA Skin Sciences Inc.|Enterprise Value to EBITDA Ratio GlucoTrack Inc. (GCTK)|EV/EBITDA Multiple NAOV|VERO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuwellis NUWE|AEMD: Enterprise Value to Operating Income Before Depreciation|ASXC: Enterprise Value to EBITDA Ratio|Avinger Inc - Enterprise Value to Operating Income Before Depreciation Ratio|BSGM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cutera.com|Enterprise Value to EBITDA Ratio KNW|Company Value to EBITDA Inari Medical Inc NARI|Enterprise Value to EBITDA Ratio NVRO (Nevro Corporation)|Enterprise Value to Operating Income Before Depreciation Ratio RSLS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Silk Road Medical, Inc SILK
